Novel application of Hsa-miR-182 genes

The invention relates to novel application of Hsa-miR-182 genes. The expression level change of miRNA has certain relevance with lung cancer staging. The expression amount of miR-182 in blood serum of NSCLC early-stage patients is remarkably improved when being compared with other stages, so that th...

Full description

Saved in:
Bibliographic Details
Main Authors MA ZHONGLIANG, JIN YOUXIN, YUAN TIANWEI, XIA YUQING, WEI JIALI, WANG QIANG, WANG DETAO
Format Patent
LanguageEnglish
Published 26.08.2015
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to novel application of Hsa-miR-182 genes. The expression level change of miRNA has certain relevance with lung cancer staging. The expression amount of miR-182 in blood serum of NSCLC early-stage patients is remarkably improved when being compared with other stages, so that the Hsa-miR-182 genes are possible to become potential marks of NSCLC blood serum detection. The novel application is the first-time report of taking Hsa-miR-182-5p as a lung cancer patient blood serum circulating miRNA mark, and has a certain application value for clinically detecting lung cancers.
Bibliography:Application Number: CN20151238477